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Appendix Table 1 
A: Final Logistic Regression Model* for SVR Status Using Stepwise Variable Selection&  
     Population: Randomized Patients Who Received at Least One Dose of Study Medication  
 
 
Effect Odds Ratio 95% CI P - Value 
METAVIR Fibrosis ( F0/1/2 vs F3/4) 2.163 1.627-2.874 <.001 
Baseline viral load (IU/mL, ≤  600,000  vs  >600,000) 3.319 2.688-4.099 <.001 
Race ( Caucasian vs African American) 3.039 2.396-3.855 <.001 
Hepatic steatosis (No: 0% vs Yes: >0%) 1.608 1.358-1.903 <.001 
Baseline fasting glucose (mmol/L, <5.6 vs ≥ 5.6) 1.428 1.185-1.721 <.001 
ALT ( Elevated vs Normal) 1.332 1.080-1.644 0.007 
 
 
 
B: Final Logistic Regression Model* for Relapse Status Using Stepwise Variable Selection& 
     Population: Patients Who Were HCV-RNA Negative at End of Treatment and Whose  
End of Follow-Up Evaluation Was Not Missing 
 
 
 
Effect Odds Ratio 95% CI P - Value 
Treatment         ( Peg2b 1.0/RBV vs Peg2a/RBV) 0.592 0.436 - 0.803 <0.001 
Treatment         ( Peg2b 1.5/RBV vs Peg2a/RBV) 0.713 0.534 - 0.951 0.02 
METAVIR Fibrosis ( F3/4 vs  F0/1/2) 1.956 1.307 - 2.928 0.001 
Baseline viral load (IU/mL, >600,000 vs ≤ 600,000) 2.633 1.872 - 3.705 <0.001 
Age(Years, >40 vs ≤ 40) 2.053 1.368 - 3.080 <0.001 
Hepatic steatosis (Yes: >0% vs  No: 0%) 1.477 1.136 - 1.920 0.004 
Baseline fasting glucose (mmol/L, ≥ 5.6 vs <5.6) 1.554 1.185 - 2.039 0.002 
ALT (Normal vs  Elevated) 1.469 1.073 - 2.012 0.02 
*Potential predictors included the following pre-specified factors: treatment regimen (Peg2b 1.0/RBV, Peg2b 
1.5/RBV, Peg2a/RBV), METAVIR fibrosis ( F0/1/2, F3/4), baseline viral load (IU/mL, ≤ 600,000,  >600,000), 
age(years, ≤ 40,  >40), gender (Male, Female), race (Caucasian, African American), hepatic steatosis (No: 0%, Yes:   
>0%), BMI (≤ 20, >20-25, >25-30, >30), ALT( Elevated , Normal), smoking status (Current, Former, Never), 
baseline genotype(1A, 1B), assigned ribavirin dose(mg/kg/day, continuous) $, baseline weight (kg, continuous) $, as 
well as the following three post-hoc factors: baseline fasting glucose (mmol/L, <5.6,  ≥ 5.6), baseline hemoglobin 
(g/dL, continuous) $, and baseline platelet count (continuous) $. 
& Model selection: stepwise selection procedure used a significance level of 0.05 for variables to both enter and stay 
in the final model. 
$All continuous variables (baseline hemoglobin, baseline platelet count, assigned ribavirin dose, and baseline 
weight) were standardized as: (variable value – mean)/Standard Deviation. 
 
Appendix Table 2:  P-Values[1] for Treatment by Subgroup Interactions and Other Model        
Effects for Subgroups Based on Patient Characteristics at Baseline 
 
                                                                  Treatment Effect Specification (Pairwise) [2]                                           
Subgroup/Effect                   (Peg2b 1.0, Peg2b 1.5)     (Peg 2b1.5, Peg 2a)     (Peg2b 1.0, Peg 2a) 
 
METAVIR Fibrosis ( 0/1/2, 3/4)                          
   Treatment                               0.29   0.50    0.71 
   Subgroup     <0.001  <0.001   <0.001 
   Treatment*Subgroup    0.06   0.75    0.11  
Baseline viral load (IU/mL, >600,000,  ≤ 600.000) 
 0.35   0.10 
1                   1 
ace (African American, Caucasian)
   Treatment                               0.47  
   Subgroup                                <0.001  <0.00        <0.00
   Treatment*Subgroup              0.99   0.41                             0.40 
 
R  
  0.44                        0.02 
                     1 
ge (Years, ≤ 40, >40)
   Treatment                               0.12 
   Subgroup                               <0.001       <0.001                    <0.00
   Treatment*Subgroup              0.18                         0.62                      0.06 
 
A  
 0.23   0.60   0.08 
ender (Male, Female)
   Treatment     
   Subgroup    <0.001   <0.001   <0.001 
   Treatment*Subgroup   0.46   0.67   0.23 
 
G  
 0.19   0.83   0.12 
epatic steatosis (No, Yes)
   Treatment   
   Subgroup    0.38                     0.04   0.70 
   Treatment*Subgroup  0.01   0.20   0.23 
 
H  
 0.50    0.41   0.14 
MI (≤ 20, >20-25, >25-30, >30)
   Treatment   
   Subgroup    <0.001   <0.001   <0.001 
   Treatment*Subgroup  0.88   0.94   0.94 
 
B  
0.80   0.42   0.27 
LT (Normal, Elevated)
   Treatment    
  Subgroup    0.87   0.76   0.26 
   Treatment*Subgroup  0.18   0.16   0.97 
 
A  
 0.88   0.36   0.44 
   Treatment*Subgroup  0.20   0.37   0.68 
   Treatment   
   Subgroup    0.04   0.01   0.24 
 
Smoking status (Current, Former, Never) 
  
   Subgroup    0.45 
   Treatment*Subgroup  0.13   0.29   0.70 
 
 Treatment    0.47   0.60   0.21 
  0.17   0.94 
Baseline fasting glucose (mmol/L, <5.6, ≥ 5.6) 
   Treatment    0.51   0.43   0.15 
 <0.001   <0.001    Subgroup    <0.001  
   Treatment*Subgroup  0.98   0.53   0.55 
 
Baseline genotype (1a, 1b) 
  
   Subgroup   
   Treatment*Subgroup  0.92   0.66   0.84 
 
 Treatment    0.97   0.97   0.97 
 0.86   0.46   0.41 
Baseline weight (kg, continuous) 
   Treatment    0.81   0.36   0.25 
0.51   0.11   0.14    Subgroup     
   Treatment* Subgroup  0.94   0.39   0.36 
 
Hemoglobin (g/dL, continuous)  
  
   Subgroup    
   Treatment * Subgroup  0.57   0.50   0.21 
 
 Treatment    0.52   0.47   0.18 
0.61   0.07   0.23 
)Platelet count (continuous  
 Treatment    0.28   0.87   0.36 
 0.006   <0.001   0.006 
  
   Subgroup   
   Treatment*Subgroup   0.17   0.99   0.17 
 
Assigned ribavirin dose (mg/kg/day, continuous) 
   Treatment     0.52   0.88   0.34 
 0.03   0.003 
al p-v fo  the co respon del eff ct, obt from a 
p, 
   Subgroup    0.01  
   Treatment* Subgroup            0.57   0.84   0.36 
                                                                                                                                                 
 [1] Table entries are the nomin alues r r ding mo e ained 
logistic regression model with SVR status as the dependent variable and treatment, subgrou
and the treatment by subgroup interaction as independent variables. 
 [2] Treatment effect is a variable with two levels which correspond to the two treatment 
regimens specified in the column heading. 
 
